Skip to main content

BNGO

Stock
Health Care
Medical Instruments & Supplies

Performance overview

BNGO Price
Price Chart

Forward-looking statistics

Beta
1.76
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.

Company info

SectorHealth Care
IndustryMedical Instruments & Supplies
Employees328
Market cap$59.9M

Fundamentals

Enterprise value$11.2M
Revenue$28.5M
Revenue per employee
Profit margin-294.05%
Debt to equity38.22

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$53.53
Dividend per share
Revenue per share$16.50
Avg trading volume (30 day)$227K
Avg trading volume (10 day)$275K
Put-call ratio

Macro factor sensitivity

Growth+1.5
Credit+9.3
Liquidity-4.8
Inflation-3.8
Commodities-2.7
Interest Rates-5.1

Valuation

Dividend yield0.00%
PEG Ratio-6.88
Price to sales0.40
P/E Ratio-6.88
Enterprise Value to Revenue0.39
Price to book0.22

Upcoming events

Next earnings dayAugust 6, 2025
Next dividend day
Ex. dividend day

News

Bears are Losing Control Over Bionano Genomics (BNGO), Here's Why It's a 'Buy' Now

Bionano Genomics (BNGO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Investment Research (September 6, 2024)
Bionano Genomics Preliminary Q4, FY21 Revenue Exceed Expectations

Bionano Genomics Inc (NASDAQ: BNGO) posted preliminary Q4 sales of $5.8 million - $6.2 million, +25% - 33% sequentially, up 45% - 55% Y/Y, and above the consensus of $5.44 million. FY21 revenue is expected to be $17.5 million - $17.9 million (consensus $17.13 million), more than doubled from FY20.

Benzinga (January 12, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free